On Wednesday, Thermo Fisher Scientific Inc. (NYSE: TMO) posted a first-quarter revenue of $10.34 billion, down 3% year over year, beating the consensus of $10.17 billion. Organic revenue was 4% lower, and core organic revenue growth declined by 3%. Revenue from the Life Sciences Solutions Segment declined by 12.5% to $2.29 billion. Analytical Instruments Segment sales were down 2.1% to $1.69 billion.  Specialty Diagnostics Segment revenues were almost flat at $1.1 billion, and Laboratory Products ...